Janssen Pharmaceutical Inc.
NEWS
Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.
New report highlights major gaps in understanding and significant misperceptions about blood cancer in the region, with one in two Japanese and one in four Chinese unable to name a single symptom of the disease
MorphoSys AG announced today that its licensee Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) has announced new data that, according to a press released issued by Janssen on September 12, 2018
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
Nearly two months ahead of the planned PDUFA date, the U.S. Food and Drug Administration approved two new HIV-1 treatments developed by Merck. The FDA gave the go ahead for Delstrigo, a once-per day triple combination treatment and Pifeltro, a new non-nucleoside reverse transcriptase inhibitor.
Janssen Pharmaceutical and Bayer saw the good, the bad and the potential for ugly this week with their blockbuster blood-thinner Xarelto (rivaroxaban). The drug gained approval for a new indication in Europe, failed a late-stage trial and is staring down the barrel of patent loss in 2023 while battling legal threats.
As the U.S. Food and Drug Administration begins to take aim at updating its 40-year-old draft guidance on drugs that treat major depressive disorder (MDD), three drugmakers with key business in that space are raising some concerns.
Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.
JOBS
IN THE PRESS